Fintech PR
Greenberg Traurig To Combine With Elite Italian Boutique Santa Maria Studio Legale And Adds Real Estate And Finance Stars, In Milan
Reading Time: 3 minutes
Global law firm Greenberg Traurig, LLP, one of the largest in the United States, announced that effective July 1, 2019, it will combine with its longstanding ally Santa Maria Studio Legale, a truly elite Italian boutique, and simultaneously add stars in the real estate and finance fields from Freshfields in Milan. The result will be Greenberg Traurig’s 40th office worldwide and its fifth in Europe, located in Milan, Italy.
“After almost 15 years of closely working together, we are pleased to welcome Professor Alberto Santa Maria, one of Europe’s leading authorities in competition and corporate law, along with Luigi Santa Maria, Mario Santa Maria, and all their partners, associates, and staff, into the GT family,” said Richard A. Rosenbaum, Executive Chairman of Greenberg Traurig. Rosenbaum has been responsible for the execution of the plan which has resulted in offices in Amsterdam, Berlin, London, Warsaw, and now Milan, in addition to Tel Aviv. Collectively, these offices employ more than 300 lawyers and are known for their exceptionally high quality, particularly in real estate, M&A, private equity and funds, finance, restructuring, tax, capital markets, media and entertainment, and other areas.
“This is a unique opportunity given our close relationship with Studio Santa Maria and its highly regarded place in the Italian market. We are a global firm, with one of the largest U.S. footprints and now over 300 lawyers across Europe, as well as a compelling strategic penetration of both Latin America and Asia. For more than 50 years, we have guarded our unified, collaborative, and non-bureaucratic culture as we have grown, maintaining our core values of excellence and sincere respect and trust of the individuals on the ground in all our locations. This unique combination has resulted in a broad and deep platform while retaining the feeling of empowerment and ability to change, which is so crucial to delivering results for our clients and satisfaction for our professionals worldwide,” Rosenbaum continued.
“Our unique approach has quickly provided us the opportunity to also simultaneously welcome the leading real estate and finance lawyers in the market for the last several decades, Marzio Longo and Corrado Angelelli, from the Freshfields firm. They will enhance our ability to take advantage of the real estate, finance, and distressed asset opportunities we believe will drive value to our private equity, real estate, banking, and other clients from our earliest days in Milan.”
Luigi Santa Maria, along with Mario Santa Maria, will become shareholders and will serve as co-managing shareholders of Greenberg Traurig’s Milan office, which will be known as Greenberg Traurig Santa Maria in Italy. Longo and Angelelli will join from Freshfields Bruckhaus Deringer, where they both practiced for decades. Longo was head of that firm’s Real Estate Practice in Italy and Angelelli was a leading finance partner in the firm’s global transactions group.
Santa Maria Studio Legale has been a leading independent law firm in Italy for over 50 years, operating internationally with a sophisticated team assisting clients in matters involving European Union law, international contracts and litigation, M&A, corporate law, and finance. In 2005, Greenberg Traurig and Santa Maria established an alliance relationship that included an Italian Desk at Greenberg Traurig’s New York City office.
“We are extremely proud of what we have been able to achieve for clients together and will now have the capability to do so as one ever-expanding platform,” Luigi Santa Maria said. “Beyond our legal experience, we look forward to bringing to our clients the technological know-how, including the use of artificial intelligence, crucial in the context of the epic change our profession is undergoing. Lawyers who make the difference and are supported by latest-generation technology, can achieve more for clients. We are also very excited to welcome Marzio Longo and Corrado Angelelli to Greenberg Traurig Santa Maria.”
Longo, with over 25 years of experience, has in-depth knowledge of all aspects of real estate consultancy, and has dealt with M&A transactions, development projects, co-investment structures such as joint ventures, and financing. He assists high-profile national and international players in the real estate market, such as private equity companies, sovereign funds and pension funds, investment funds, and companies involved in real estate development.
“Both Greenberg Traurig and the team at Santa Maria Studio Legale have always had an excellent reputation that go beyond legal expertise. Specifically, I look forward to having clients work with the award-winning real estate team not only here in Italy, but also worldwide. And I am confident that my experience will prove to be of value to clients across markets,” Longo said.
Angelelli is among the most experienced lawyers in Italy in the field of structured finance, having assisted many clients in securitization transactions concerning a wide range of asset classes. In addition, he has gained experience in restructuring, real estate financing and refinancing, has a strong expertise in NPLs and has aided clients with the legal aspects of the purchase and sale of loan and asset portfolios.
“Given that I assist foreign banks and investors, Italian companies, and financial institutions, the move to Greenberg Traurig Milan was an easy decision to make,” Angelelli said. “This is a highly sophisticated team that works well together across platforms, markets, and sectors. I look forward to expanding my reach and adding to the team’s already robust global capabilities.”
Robert J. Ivanhoe, co-chair of Greenberg Traurig’s Global Real Estate Practice, added, “It has been my pleasure getting to know Marzio and Corrado, they are top quality individuals who will fit well with both our dear friends at Santa Maria and with GT globally, and we can’t wait to explore the many opportunities before us.”
SOURCE Greenberg Traurig, LLP
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
-
Latest News7 days ago
Bitrue Gears Up for 2024 Bitcoin Halving with Trading Competition
-
Latest News6 days ago
Global Airlines Appoints New Head of Finance from KPMG
-
Latest News5 days ago
“The Hainan FTP and Me”: Looking at Hainan’s Transformations
-
Latest News6 days ago
Spendesk combines procurement with spend management through Okko acquisition
-
Latest News7 days ago
BtcTurk Organizes Half Marathon in Istanbul to Celebrate Halving Period
-
Latest News4 days ago
Millions of people unite around doing good on the 18th International Good Deeds Day held yesterday worldwide
-
Latest News7 days ago
Bitget to Take Center Stage at Blockchain Life and Token2049 Dubai